EGFR and non-small cell lung carcinoma: Although either downregulation of EGFR and ErbB2 or increased ErbB3 expression upon treatment with HDACi have been reported before in tumor cells and particularly in NSCLC cell lines [16, 29, 36–40], to our knowledge this is the first study reporting these effects in primary cultures.